Constructing Protective Recombinant Vaccines
The company was established in 2009 in Vienna, Austria as a biotech consulting firm. It was later rebranded as Capricorn Consilium GmbH (Ltd.). Since mid-2017, Capricorn Consilium has been working on vaccine projects, a shift prompted by the addition of Prof. Dr. A. Egorov to the team.
In 2023, the company was acquired and fully restructured by new owners, who introduced numerous innovative technologies for vaccine development from Capricorn’s sister companies. A new management board was appointed, and the company was renamed Capricorn Technologies GmbH.
Since 2018, Capricorn has developed and accumulated various inventions and expertise, including methods for constructing safe influenza vectors, a high-throughput clone of the Vero cell line, and an effective method for purifying vaccine candidates. Experimental samples of a universal influenza vaccine and a circovirus vaccine for pigs have also been developed. Convincing evidence of the safety and immunogenicity of these drugs has been obtained when administered intranasally to 8-week-old piglets. Ongoing studies are investigating the effectiveness of veterinary vaccines when administered intradermally.
Meet the Team
| Dr. Pavel Loiteries, PhD Chairman of the Board | Dr. Sergey V Litvinov, PhD Chief Business Development, Member of the Board |
| Dr. Andrey Egorov Chief Science Officer, Member of the Board | Helmut Schmutz Chief Executive Officer |
| Dr. Artem Krokhin, PhD Head of the Laboratory |
Our Partners and Collaborators
